Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
about
Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?Individualization of antiretroviral therapy--pharmacogenomic aspectAtazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic ReviewEvaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Relationship between microbial translocation and endothelial function in HIV infected patients.Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Switching antiretroviral therapy to minimize metabolic complications.Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitusComparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapyHIV stroke risk: evidence and implications.The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population.Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy.Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues.Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.Cardiovascular disease in patients with HIVHIV protease inhibitors: present and futureFrom lipodystrophy to cardiovascular disease: new insight into the management of HIV infection
P2860
Q27026486-AD89D387-C794-4AA9-ABAC-4B2D7E3EEC64Q28070574-DCCF1EEE-AE6D-45D0-98E2-0A4B69C6DD78Q28080289-E5E4CF12-8ECA-49D0-88FB-AC6F91AB3202Q31118978-277A0535-EFB2-4D64-9D46-A134DF3C1478Q34404759-D2FF9705-CD95-49F3-A4DF-3FE2D7F77292Q34730407-2FB7D24E-0C7A-4E63-89E6-F9D4F4B7369AQ35079510-C116F577-DEB2-4A6D-B48F-2AB7159F10CEQ35608074-905C4D0A-5AA9-448D-AF2F-61BA7BA7F659Q35832866-6AE9E5B6-EB9D-47B4-8BBC-AFA8308DDCDEQ36116238-E463E259-456A-4830-A248-89BD1D490383Q36198944-97387E78-0F98-4511-AFBB-D64214A82D3FQ36722756-13EA0CAC-04EF-4B0F-B48B-4120102082A1Q36951676-D67307BF-E75F-41F4-8267-D62169BCDEAAQ37250997-5B5F16DF-28B8-4585-A267-82EF84F3D767Q40070894-15A594C2-F9CA-4610-8094-47A5E7A7636FQ40627833-D83E5759-87BA-4DAC-9ABC-F03AE3E1703EQ41986602-D17E6727-6DB1-4FE3-A369-87EE7ECC081AQ42243725-8AE2C112-8023-4C8C-8B15-4312FCB17E81Q42278370-9484D736-8136-4D75-A6E8-601C21EA145DQ46714887-69B97905-E159-45AC-BB24-422EA2BCC026Q57681411-EF2708D5-04C1-42F8-B948-F23DFB7F9AB3Q58290794-7464040B-E685-415D-866B-0A778865E6F1Q58798012-2947EB71-E388-47BA-8AC5-1E8202E59F6F
P2860
Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@en
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@nl
type
label
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@en
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@nl
prefLabel
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@en
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@nl
P2093
P50
P1433
P1476
Change to atazanavir/ritonavir ...... stable antiretroviral therapy.
@en
P2093
Baiba Berzins
Carlos Zala
Carol Mitchell
Elizabeth Belsey
Francesca Torriani
Michael P Dube
SABAR Study Team
P304
P356
10.1097/QAD.0B013E3283352ED5
P407
P577
2010-03-01T00:00:00Z